Somatostatin Receptor Scintigraphy with ¹¹¹In- Pentetreotide for Detection of Atypical Metastatic Localization of a Midgut Neuroendocrine Tumor: A Case Study

Lyonel Belia, Eddy Glaude, Caroline Faes, Thibault Michelin, Mona Hedreville, Mathon Grégory, Ulises Jáuregui-Haza and Fritz-Line Vélayoudom-Céphise

Department of Endocrinologie, University Hospital of Pointe-à-Pitre, Cuba
Department of Endocrinologie, University of Havana, Cuba
Department of Endocrinologie, University of the French West Indies, Cuba

^*Correspondance to: Fritz-Line Vélayoudom-Céphise 

 PDF  Full Text Case Report | Open Access

Abstract:

A 49-year-old man was referred to the University Hospital of Pointe-à-Pitre for abdominal pains. He underwent a midgut neuroendocrine tumor (NET) resection 8 years ago. The computed tomography revealed multiple liver metastases. ¹¹¹In-pentetreotide, SPECT/CT identified liver metastases and a suspect cardiac uptake. A cardiac magnetic resonance imaging confirmed a thickening of the bottom wall of the heart, measuring 24 mm compatible with a cardiac metastasis of the NET.¹¹¹In-Pentetreotide SPECT/CT remains a good functional imaging compared to conventional somatostatin receptor scintigraphy to precise anatomical localization of NET metastases and could help to select the best morphological imaging to complete the staging of metastatic NET. The delayed detection of the cardiac metastasis did not allow setting up an effective management and the patient dead due to an uncommon hepatic metastasis compression of the heart.

Keywords:

Neuroendocrine tumor; Somatostatin receptor scintigraphy; ¹¹¹In-pentetreotide

Cite the Article:

Belia L, Glaude L, Faes C, Michelin T, Hedreville M, Grégory M, et al. Somatostatin Receptor Scintigraphy with ¹¹¹In-Pentetreotide for Detection of Atypical Metastatic Localization of a Midgut Neuroendocrine Tumor: A Case Study. Ann Clin Case Rep. 2018; 3: 1488.